Literature DB >> 9355973

Genetic alterations in lobular breast cancer by comparative genomic hybridization.

T Nishizaki1, K Chew, L Chu, J Isola, A Kallioniemi, N Weidner, F M Waldman.   

Abstract

Infiltrating lobular carcinoma (ILC) and infiltrating ductal carcinoma (IDC) are distinguished by their histopathological appearance. However, little is known about the differences in genetic changes between lobular cancers and ductal cancers. We used comparative genomic hybridization (CGH) and compared aberrations in 19 ILCs and 46 IDCs. The total number of aberrations was lower in ILC than in IDC. While the average number of DNA copy number losses did not reach significance between them, copy number gains were significantly lower in ILCs. Fifteen of 19 ILCs (79%) showed increased copy number of 1q, and 12 cases (63%) revealed loss of 16q. The presence of these aberrations was independent of nodal status, histologic subtypes (pleomorphic or classic ILC), or BrdUrd-labeling index. ILCs had a higher frequency of 16q loss than did ductal cancers, and a lower frequency of 8q and 20q gains. Our data suggest that the altered growth pattern and clinical presentation which characterize infiltrating lobular cancers are correlated with distinct genetic alterations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355973     DOI: 10.1002/(sici)1097-0215(19971021)74:5<513::aid-ijc6>3.0.co;2-6

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma.

Authors:  S Ozaki; T Nishizaki; H Ito; K Sasaki
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 2.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

3.  Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population.

Authors:  Amanda I Phipps; Christopher I Li; Karla Kerlikowske; William E Barlow; Diana S M Buist
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

4.  Testing clonal relatedness of tumors using array comparative genomic hybridization: a statistical challenge.

Authors:  Irina Ostrovnaya; Colin B Begg
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

5.  Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.

Authors:  Lan Cao; Ahmed Basudan; Matthew J Sikora; Amir Bahreini; Nilgun Tasdemir; Kevin M Levine; Rachel C Jankowitz; Priscilla F McAuliffe; David Dabbs; Sue Haupt; Ygal Haupt; Peter C Lucas; Adrian V Lee; Steffi Oesterreich; Jennifer M Atkinson
Journal:  Cancer Lett       Date:  2019-06-20       Impact factor: 8.679

Review 6.  Preinvasive breast cancer.

Authors:  Dennis C Sgroi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

Review 7.  [Lobular neoplasms and invasive lobular breast cancer].

Authors:  H-P Sinn; B Helmchen; J Heil; S Aulmann
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

8.  Chromosome 8 numerical aberrations in stage II invasive ductal carcinoma: correlation with patient outcome and poor prognosis.

Authors:  Yutaka Tagawa; Toru Yasutake; Yasushi Ikuta; Tadayuki Oka; Ryusuke Terada
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

9.  Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma.

Authors:  Cristina Riva; Emanuele Dainese; Giacomo Caprara; Paolo Cossu Rocca; Giovanni Massarelli; Tibor Tot; Carlo Capella; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

10.  Increased levels of active c-Src distinguish invasive from in situ lobular lesions.

Authors:  Donghui Zou; Han-Seung Yoon; Ahmad Anjomshoaa; David Perez; Ryuji Fukuzawa; Parry Guilford; Bostjan Humar
Journal:  Breast Cancer Res       Date:  2009-07-07       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.